A study found that COVID-19 could cause a dysregulation of lipid metabolism which eventually contributes to insulin resistance.22 Another study reported that as a result of ACE2 downregulation following the SARS-CoV-2 infection, insulin resistance could be developed owing to the exaggeration of angiotensin II.23 During the treatment in the hospital, there was a significant increase of patients receiving sodium-glucose linked transporter (SGLT) inhibitors and insulin therapies. The gene discussed is ACE2; the disease is COVID-19.